Fig. 3.

γδ T-APCs induce CD8⁺ T cell-mediated antitumor effects against osteosarcoma in vivo. HOS cells co-transfected with MAGEA3 and luciferase were inoculated subcutaneously into the left thighs of NOD-SCID mice. γδ T cells stimulated by zoledronate and IL-2 for 10 days were used as γδ T-APCs. After 7 days, mice started to receive the injection of CD8⁺ T cells, respectively, stimulated by peptide non-pulsed γδ T-APCs, irrelevant peptide-pretreated γδ T-APCs (γδ T-IP) or MAGEA3-pretreated γδ T-APCs (γδ T-MAGEA3) via the tail vein. A Mice were euthanized on the 18th day and the tumors were excised. B Tumor volumes were measured every 2 days, starting on the 8th day. C Mice were imaged with the in vivo imaging system on the 10th, 13th and 16th days. Tumor growth was evaluated by visualizing bioluminescence, and T cell migration was detected by DiR fluorescence. D Intratumoral CD8⁺ T cells were detected by immunohistochemical assays (shown in brown). E Quantification of CD8⁺ T cells infiltration was shown in histogram. Representative data were shown from 2 independent experiments. All the values were presented as mean ± SD. ***p < 0.001 versus Control. ###p < 0.001